Skip to main content

Table 1 Baseline characteristics of patients

From: Feasibility and efficacy of helical tomotherapy in cirrhotic patients with unresectable hepatocellular carcinoma

Variables No. of patients (%)
Age (years)  
 Median 67
 Range 45–85
Gender  
 Male 31 (81.6)
 Female 7 (18.4)
ECOG score  
 0–1 24 (63.2)
 2 14 (36.8)
Etiology  
 Hepatitis B 21 (55.3)
 Hepatitis C 11 (28.9)
 Alcohol 6 (15.8)
Child-Pugh classification  
 A 27 (71.1)
 B 11 (28.9)
Alpha-fetoprotein (ng/ml)  
 Median 50.6
  ≤ 400/>400 23 (60.5)/15 (39.5)
Albumin (g/dL)  
 Median 3.6
 Range 2.39–4.54
Hemoglobin (g/dL)  
 Median 11.4
 Range 8.2–16
AJCC tumor stage  
 T1–2 8 (21.1)
 T3–4 30 (78.9)
Tumor size(cm)  
 Median (range) 4.6 (2.5–16.7)
  ≤ 4/>4 10 (26.3)/28 (73.7)
PVTT  
 Yes 24 (63.2)
 No 14 (36.8)
Previous treatment  
 TACE 29
 PEI or RFA 18
 None 3
  1. PVTT portal vein tumor thrombus, ECOG Eastern Cooperative Oncology Group, TACE transcatheter hepatic arterial chemoembolization, PEI percutaneous ethanol injection, RFA radiofrequency ablation, AJCC American Joint Committee on Cancer